Join our daily newsletter At The Bell to receive exclusive market insights
- Vection Technologies (VR1) has lodged a patent application to cover the technology used in its augmented reality (AR) healthcare solutions
- The application was filed with the Italian Patent and Trademark Office and, if granted, will pave the way for future patent grants in the European Union and allow for possible protections in Australia and the U.S.
- This news follows Vection’s recent trial agreement to test its AR healthcare solutions
- This trial will focus on AR in endoscopic surgery and electronic medical record system access through wearable devices
- Vection is up 4.49 per cent and shares are trading for 8.5 cents each
Vection Technologies (VR1) has lodged a patent application to cover the technology used in its augmented reality (AR) healthcare solutions.
The application is titled “Method for customisation and re-execution of video sequences in a virtual world” and was filed with the Italian Patent and Trademark Office.
If granted, this will pave the way for future patent grants in the European Union and allow for possible protections in Australia and the U.S.
This news follows Vection’s recent trial agreementto test its AR healthcare solutions with Moscati hospital and Luiss Liberia Università Internazionale deluge Studi Sociali Guido Carli.
This trial will focus on AR in endoscopic surgery and electronic medical record system access through wearable devices.
Vection claims this trial is critical in introducing AR solutions in hospitals and the Italian healthcare sectors.
“The lodgement of this patent represents an additional step forward in the company’s overarching strategy and, if granted, will enable the company to protect its interests within the healthcare market segment,” Managing Director Gianmarco Biagi said.
Vection is up 4.49 per cent and shares are trading for 8.5 cents each at 1:52 pm AEST.
